These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 29065825)
21. Gender-Specific Effects of Two Treatment Strategies in a Mouse Model of Niemann-Pick Disease Type C1. Holzmann C; Witt M; Rolfs A; Antipova V; Wree A Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33802605 [TBL] [Abstract][Full Text] [Related]
22. Transcriptome of HPβCD-treated Niemann-Pick disease type C1 cells highlights GPNMB as a biomarker for therapeutics. Rodriguez-Gil JL; Baxter LL; Watkins-Chow DE; Johnson NL; Davidson CD; Carlson SR; Incao AA; ; Wallom KL; Farhat NY; Platt FM; Dale RK; Porter FD; Pavan WJ Hum Mol Genet; 2021 Nov; 30(24):2456-2468. PubMed ID: 34296265 [TBL] [Abstract][Full Text] [Related]
24. In Niemann-Pick C1 mouse models, glial-only expression of the normal gene extends survival much further than do changes in genetic background or treatment with hydroxypropyl-beta-cyclodextrin. Marshall CA; Watkins-Chow DE; Palladino G; Deutsch G; Chandran K; Pavan WJ; Erickson RP Gene; 2018 Feb; 643():117-123. PubMed ID: 29223359 [TBL] [Abstract][Full Text] [Related]
25. Cyclodextrins in the treatment of a mouse model of Niemann-Pick C disease. Camargo F; Erickson RP; Garver WS; Hossain GS; Carbone PN; Heidenreich RA; Blanchard J Life Sci; 2001 Nov; 70(2):131-42. PubMed ID: 11787939 [TBL] [Abstract][Full Text] [Related]
26. Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. Davidson CD; Ali NF; Micsenyi MC; Stephney G; Renault S; Dobrenis K; Ory DS; Vanier MT; Walkley SU PLoS One; 2009 Sep; 4(9):e6951. PubMed ID: 19750228 [TBL] [Abstract][Full Text] [Related]
27. Intrathecal 2-hydroxypropyl-beta-cyclodextrin in a single patient with Niemann-Pick C1. Maarup TJ; Chen AH; Porter FD; Farhat NY; Ory DS; Sidhu R; Jiang X; Dickson PI Mol Genet Metab; 2015; 116(1-2):75-9. PubMed ID: 26189084 [TBL] [Abstract][Full Text] [Related]
28. Cyclodextrins, blood-brain barrier, and treatment of neurological diseases. Vecsernyés M; Fenyvesi F; Bácskay I; Deli MA; Szente L; Fenyvesi É Arch Med Res; 2014 Nov; 45(8):711-29. PubMed ID: 25482528 [TBL] [Abstract][Full Text] [Related]
30. Anesthetic management of pediatric patients with Niemann-Pick disease type C for intrathecal 2-hydroxypropyl-β-cyclodextrin injection. Ulloa ML; Froyshteter AB; Kret LN; Chang DP; Sarah GE; McCarthy RJ; Barnes SD; Berry-Kravis EM Paediatr Anaesth; 2020 Jul; 30(7):766-772. PubMed ID: 32349180 [TBL] [Abstract][Full Text] [Related]
31. Long-Term Neuropsychological Outcomes from an Open-Label Phase I/IIa Trial of 2-Hydroxypropyl-β-Cyclodextrins (VTS-270) in Niemann-Pick Disease, Type C1. Farmer CA; Thurm A; Farhat N; Bianconi S; Keener LA; Porter FD CNS Drugs; 2019 Jul; 33(7):677-683. PubMed ID: 31187454 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of Two Liver Treatment Strategies in a Mouse Model of Niemann-Pick-Disease Type C1. Ebner L; Gläser A; Bräuer A; Witt M; Wree A; Rolfs A; Frank M; Vollmar B; Kuhla A Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29587349 [TBL] [Abstract][Full Text] [Related]
33. Application of N-palmitoyl-O-phosphocholineserine for diagnosis and assessment of response to treatment in Niemann-Pick type C disease. Sidhu R; Kell P; Dietzen DJ; Farhat NY; Do AND; Porter FD; Berry-Kravis E; Vite CH; Reunert J; Marquardt T; Giugliani R; Lourenço CM; Bodamer O; Wang RY; Plummer E; Schaffer JE; Ory DS; Jiang X Mol Genet Metab; 2020 Apr; 129(4):292-302. PubMed ID: 32033912 [TBL] [Abstract][Full Text] [Related]
34. Defective Cytochrome P450-Catalysed Drug Metabolism in Niemann-Pick Type C Disease. Nicoli ER; Al Eisa N; Cluzeau CV; Wassif CA; Gray J; Burkert KR; Smith DA; Morris L; Cologna SM; Peer CJ; Sissung TM; Uscatu CD; Figg WD; Pavan WJ; Vite CH; Porter FD; Platt FM PLoS One; 2016; 11(3):e0152007. PubMed ID: 27019000 [TBL] [Abstract][Full Text] [Related]
35. Visual evoked potentials of Niemann-Pick type C1 mice reveal an impairment of the visual pathway that is rescued by 2-hydroxypropyl-ß-cyclodextrin. Palladino G; Loizzo S; Fortuna A; Canterini S; Palombi F; Erickson RP; Mangia F; Fiorenza MT Orphanet J Rare Dis; 2015 Oct; 10():133. PubMed ID: 26458950 [TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics and distribution of 2-hydroxypropyl-β-cyclodextrin following a single intrathecal dose to cats. Kao ML; Stellar S; Solon E; Lordi A; Kasica N; Swain G; Bagel JH; Gurda BL; Vite CH J Inherit Metab Dis; 2020 May; 43(3):618-634. PubMed ID: 31707730 [TBL] [Abstract][Full Text] [Related]
37. Cerebrospinal Fluid Calbindin D Concentration as a Biomarker of Cerebellar Disease Progression in Niemann-Pick Type C1 Disease. Bradbury A; Bagel J; Sampson M; Farhat N; Ding W; Swain G; Prociuk M; O'Donnell P; Drobatz K; Gurda B; Wassif C; Remaley A; Porter F; Vite C J Pharmacol Exp Ther; 2016 Aug; 358(2):254-61. PubMed ID: 27307499 [TBL] [Abstract][Full Text] [Related]
38. Collaborative development of 2-hydroxypropyl-β-cyclodextrin for the treatment of Niemann-Pick type C1 disease. Ottinger EA; Kao ML; Carrillo-Carrasco N; Yanjanin N; Shankar RK; Janssen M; Brewster M; Scott I; Xu X; Cradock J; Terse P; Dehdashti SJ; Marugan J; Zheng W; Portilla L; Hubbs A; Pavan WJ; Heiss J; Vite CH; Walkley SU; Ory DS; Silber SA; Porter FD; Austin CP; McKew JC Curr Top Med Chem; 2014; 14(3):330-9. PubMed ID: 24283970 [TBL] [Abstract][Full Text] [Related]
39. In Vitro and In Vivo Evaluation of 6-O-α-Maltosyl-β-Cyclodextrin as a Potential Therapeutic Agent Against Niemann-Pick Disease Type C. Yasmin N; Ishitsuka Y; Fukaura M; Yamada Y; Nakahara S; Ishii A; Kondo Y; Takeo T; Nakagata N; Motoyama K; Higashi T; Okada Y; Nishikawa J; Ichikawa A; Iohara D; Hirayama F; Higaki K; Ohno K; Matsuo M; Irie T Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30845767 [TBL] [Abstract][Full Text] [Related]